NCT06763146Active, not recruiting
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice
Real-world Experience With Finerenone Treatment in Patients From India With Chronic Kidney Disease and Type 2 Diabetes-Retrospective Data Analysis
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1200 (estimated)
- First submitted
- 2 Jan 2025
- Start date
- 22 Sept 2025
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Bayer
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT06763146
What you commit to
- Study type: Observational
- Planned participants: 1200
- From 22 Sept 2025 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Patient taking concomitant medications that are strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, ritonavir, nelfinavir, cobicistat, clarithromycin, telithromycin and nefazodone).
Other illness
- Type 1 diabetes is recorded in the patient record
- \- Addison's disease.
Lab values
- eGFR \<25 mL/min/1.73 m\^2
- Serum potassium \>5.0 mmol/L
Other
- Contraindications according to the local marketing authorization - Patient data will be excluded if below information is identified in the patient record at any point from index date to the end of observation period:
- \- Pregnancy.
- \- Lactation.
- Patient was a part of an interventional clinical study between 1st August 2022 and 30th Nov 2024.
Who the study is looking for
- Patients from India (Indian ethnicity) diagnosed with CKD and T2D prior to initiating finerenone (per the standard diagnostic criteria) and initiated on finerenone per approved label.
- Patient was prescribed finerenone for the first time (drug naïve) for the management of CKD and T2D between 1st August 2022 and 30th April 2024.
- Age 18 years or older at the time of finerenone initiation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Many locations Coordinator of this site? Confirm its status | Many Locations | India | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.